en · de · es · pt
peptide-index.peptides5388.com › Info › Analytical Detection And Laboratory Handling — Quick Reference

Analytical Detection And Laboratory Handling — Quick Reference

By Editorial Desk · published 2025-08-23 · last reviewed 2025-10-11 · Info

This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Handling, Analysis, and Regulation

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Sr9009 at a glance

PropertyValueNotes
AppearanceOff-white to pale yellow solidVisual description varies with purity and source
SolubilitySoluble in DMSO and ethanol; poorly soluble in waterOrganic stock solutions are common in research
Typical storage-20 °C, desiccated, protected from lightAvoid repeated freeze-thaw cycles
Typical analytical methodLC-MS or HPLC-UVReference standards are needed for quantification
Molar massApproximately 437.9 g/molCalculated from the reported free-base formula

Background and Receptor Pharmacology

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Analytical and Handling Considerations

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Further detail

=== Simplifying Peptide Synthesis === CITU—reagent for peptide synthesis and decarboxylative cross-coupling (2017) Thermodynamic peptide macrocyclization (2017) General method for chemoselective, and modular functionalization of serine residues (2020)

=== Solid microneedles === Solid MNs are the first type of MNs fabricated and are the most commonly used. Hard solid MNs have sharp tips that pierce through and form pores on the stratum corneum. A drug patch will then be applied to the skin for drug to be absorbed slowly and passively through numerous micropores. This type of array is designed as a two part system; the microneedle array is first applied to the skin to create microscopic wells just deep enough to penetrate the outermost layer of skin, and then the drug is applied via transdermal patch. Solid microneedles are already used by dermatologists in collagen induction therapy, a method which uses repeated puncturing of the skin with microneedles to induce the expression and deposition of the proteins collagen and elastin in the skin. Solid MNs help increase the permeability and absorption of drugs.

=== Inflammation phase === In the inflammatory phase, macrophages and other phagocytic cells kill bacteria, debride damaged tissue and release chemical factors such as growth hormones that encourage fibroblasts, epithelial cells and endothelial cells which make new capillaries to migrate to the area and divide.

== Production == Reactor-grade plutonium from spent nuclear fuel contains various isotopes of plutonium. 238Pu makes up only one or two percent, but it may be responsible for much of the short-term decay heat because of its short half-life relative to other plutonium isotopes. Reactor-grade plutonium is not useful for producing 238Pu for RTGs because difficult isotopic separation would be needed. Pure plutonium-238 is prepared by neutron irradiation of neptunium-237, one of the minor actinides that can be recovered from spent nuclear fuel during reprocessing, or by the neutron irradiation of americium in a reactor. The targets are purified chemically, including dissolution in nitric acid to extract the plutonium-238. A 100 kg sample of light water reactor fuel that has been irradiated for three years contains only about 700 grams (0.7% by weight) of neptunium-237, which must be extracted and purified. In the US, the Department of Energy's Space and Defense Power Systems Initiative of the Office of Nuclear Energy processes 238Pu, maintains its storage, and develops, produces, transports and manages safety of radioisotope power and heating units for both space exploration and national security spacecraft. As of March 2015, a total of 35 kilograms (77 pounds) of 238Pu was available for civil space uses. Out of the inventory, 17 kg (37 lb) remained in a condition meeting NASA specifications for power delivery.

==== Fruits ==== With conventional dehydration, berries can degrade in quality as their structure is delicate and contains high levels of moisture. Strawberries were found to have the highest quality when freeze dried; retaining color, flavor, and ability to be re-hydrated.

Sources: en.wikipedia.org

Supporting material

The DXP-independent PLP-biosynthetic route consists of a step catalyzed by Pyridoxal 5'-phosphate synthase (glutamine hydrolyzing), an enzyme composed of two subunits. PdxS catalyzes the condensation of ribulose 5-phosphate, glyceraldehyde-3-phosphate, and ammonia, this latter molecules is produced by PdxT which catalyzes the production of ammonia from glutamine. PdxS is a (β/α)8 barrel (also known as a TIM-barrel) that forms a dodecamer.

=== Tangential trapezoid === If the incircle is tangent to the sides AB and CD at W and Y respectively, then a tangential quadrilateral ABCD is also a trapezoid with parallel sides AB and CD if and only if

This reacts up to 400 fold faster than the original pair with a rate constant of 5.5 ± 0.6 × 105 M−1 s−1. This version is back reactive with the two previous generations of SpyTag/SpyCatcher reagents. SpyTag/SpyCatcher react with specificity even when in the presence of bacterial and mammalian cell environments.

== Structure == The edited sites are found within the insulin growth factor binding domain of IGFBP7 and also Heparin binding domain. This region is also a site for proteolytic cleavage. Structural analysis of the edited sites determined that the two amino acids that corresponded to the edited sites are not directly involved in binding to IGF-1 but are found in regions flanking them. At position 78 in unedited version of the transcript there is an Arginine close to residue valine-49. This Valine is important in hydrophobic interaction of Phenylalanine of IGF-1. A substitution to a Glycine at this position is thought to introduce additional flexibility leading to a change of loop conformation, thereby disrupting the hydrophobic interaction that stabilises the complex. At amino acid position 98 the unedited transcript contains a lysine. This residue makes some non specific interactions via the aliphatic part of the side chain with Glu-38 of IGF-1. In the edited version the position is an arginine. The long side chain of which is thought to be able to maintain these weak interactions.

Sources: en.wikipedia.org

Notes from published material

== Mode of action == Like other macrolides, tylosin has a bacteriostatic effect on susceptible organisms, caused by inhibition of protein synthesis through binding to the 50S subunit of the bacterial ribosome.

Fish protein concentrate (FPC) is a powder concentrate with medium level of protein (50-70%) and will contain some level of fat/oil (1-20%) in the powder form as well. Fish protein isolate (FPi) is a product containing less than 1% fat/oil and more than 90% protein. New manufacturing techniques are also producing hybrid FPi products where the fat/oil content is very low, (<0.3%) with the protein levels in the 80% range. The hybrid FPi does not reach 90% protein (often a definition point for an isolate) as the natural minerals are not removed and thus represent up to 15% of the final mass balance.

linkage The tendency of DNA sequences which are physically near to each other on the same chromosome to be inherited together during meiosis. Because the physical distance between them is relatively small, the chance that any two nearby parts of a DNA sequence (often loci or genetic markers) will be separated on to different chromatids during chromosomal crossover is statistically very low; such loci are then said to be more linked than loci that are farther apart. Loci that exist on entirely different chromosomes are said to be perfectly unlinked. The standard unit for measuring genetic linkage is the centimorgan (cM).

Russia launched about 85 to 100 missiles at a number of Ukrainian cities. The strategic bombing campaign caused severe shortages of electricity and water at multiple cities. According to the Ukrainian Air Force some 77 of 96 Russian missiles were shot down. A Pentagon official claimed the Russian plan was to exhaust the Ukrainian air defences. At one stage some 50 missiles were in combat "within minutes" near the Polish border. A missile crossed over the Ukrainian-Polish border and struck the village of Przewodów, killing two civilians. Top leaders in Poland held an emergency meeting. Initial assessments by the United States found that the missile was likely to have been an air defence missile fired by Ukrainian forces at an incoming Russian missile. According to Ukraine's Operational Command South, Ukrainian rocket and artillery units attacked Russian positions on the left bank of the Dnipro River and in the area of the Kinburn Spit.

Fujirebio is a Japanese multinational in vitro diagnostics (IVD) company, founded in 1950 and headquartered in Tokyo, Japan. The company develops, manufactures, and markets IVD testing products — including reagents, instruments, and software — for clinical diagnostics and research use. Fujirebio operates offices in Asia, Europe, and the United States, and maintains a broad international distribution network, with manufacturing facilities in Japan, Europe, and the United States. The company employs more than 1,400 people globally. Fujirebio operates an open business model in which it develops novel biomarkers and diagnostic content, validates them using its own fully-automated Lumipulse® chemiluminescent enzyme immunoassay (CLEIA) platform, and distributes them globally through partnerships and a Contract Development and Manufacturing Organization (CDMO) model — providing development, manufacturing, and regulatory services to third-party diagnostic companies. The company’s principal areas of expertise include oncology, infectious diseases, and neurological disorders. In May 2025, Fujirebio received FDA 510(k) clearance for the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based IVD test to aid in identifying amyloid pathology associated with Alzheimer’s disease. In 2022, Fujirebio acquired ADx NeuroSciences, a Belgian biotech company specializing in neurological biomarker research, for €40 million. Fujirebio is a consolidated subsidiary of H.U. Group Holdings, Inc.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

What is known about its stability?

The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.

Why does solubility matter?

Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

Network